Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy) Authors: Lalit Verma, Shweta Singh, Dinesh Talwar, Avnindra Gupta, Gauri Khare, Obuli N Ramachandran, Bhanupriya, Gaganjeet Singh Gujral, H S Harish, Nikita Gupta Published: 2026 ABSTRACT Purpose:To assess the long-term safety and efficacy of intravitreal brolucizumab (Pagenax®) in eyes with chronic central serous chorioretinopathy (CSC) complicated by neovascularization (pachychoroid neovasculopathy) refractory to prior therapies.Methods:In this single-center retrospective case series (January 2021–July 2025), 30 eyes of 25 patients with recalcitrant and refractory cases of chronic CSC with secondary neovascularization were treated off-label with pro-re-nata intravitreal brolucizumab. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and pigment epithelial detachment (PED) height were measured at baseline and 6 months, with extended outcomes in nine eyes assessed at 1 and 2 years. Adverse events were recorded at each visit.Results:At 6 months, the mean CST decreased significantly from 328 ± 222 µm to 172 ± 79 µm (P < 0.001), and the PED height declined from 262 ± 192 µm to 155 ± 123 µm (P = 0.027). BCVA improved or remained stable in 90% of eyes, with no significant change in mean logMAR (0.38 to 0.33, P = 0.314). In the extended cohort, CST reductions persisted at 1 year (412 ± 241 µm to 271 ± 239 µm, P = 0.009) and 2 years (412 ± 241 µm to 164 ± 42 µm, P = 0.004), while BCVA stayed stable. A weak correlation suggested more injections might be linked to slightly poorer BCVA, possibly due to resistant cases requiring more treatment. No adverse events were noted.Conclusion:Intravitreal brolucizumab administered PRN effectively resolves persistent fluid and reduces PED in chronic CSC with PNV refractory to prior treatments, while maintaining stable visual acuity and demonstrating a favorable safety profile through 2 years of follow-up. Central serous chorioretinopathy (CSC) is characterized by subretinal fluid accumulation and was historically viewed as a self-resolving condition. Recent advances in retinal and choroidal imaging techniques have helped ophthalmologists refine the diagnostic criteria for this condition. Based on published literature, this condition is now classified within the pachychoroid spectrum, a term first introduced by Warrow et al.[1] to describe entities associated with a thickened choroid. Pachychoroid disease includes a range of clinical phenotypes characterized by dilation of Haller’s layer of the choroid and thinning of Sattler’s layers and the choriocapillaris.[2] While earlier reports linked pachychoroid disease to increased choroidal thickness, recent research indicates that choroidal thickness is not the primary characteristic defining the condition. According to recent consensus, choroidal venous congestion and hyperpermeability due to dysfunctional retinal pigment epithelium (RPE) are recognized as the primary factors initiating the disease process and contributing to its diverse phenotypic spectrum.[3] Manifestations of chronicity in CSC can include features of RPE atrophy, persistent pigment epithelial detachments (PEDs), and damage to the photoreceptor layer, with or without choroidal neovascularization. The variant associated with choroidal thickening is termed pachychoroid neovasculopathy (PNV). Fluid accumulation in chronic CSC may originate from primary choroidal hyperpermeability or exudation from PNV.[45] Due to its potential for causing irreversible visual impairment, chronic CSC necessitates a more aggressive management approach. Currently, there is no consensus on treatment the entity. Pharmacological options, such as oral mineralocorticoid antagonists and topical steroids, have been tried.[67] Modified half-dose photodynamic therapy (PDT) has proven beneficial in such cases.[8] The PLACE trial compared half-dose PDT with high-density subthreshold micropulse laser[9]; however, owing to a global shortage of verteporfin, reliance on alternative therapies has increased. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are used off-label to manage exudation and neovascularization in pachychoroid diseases, paralleling their application in other neovascular macular conditions.[101112] Brolucizumab (Beovu®; Novartis, Basel, Switzerland), one of the anti-VEGF agents, was approved in 2019 by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (nAMD), demonstrating improved durability compared to aflibercept.[12] This drug gained approval from the Drug Controller General of India (DCGI) and was subsequently marketed under the name Pagenax® (Novartis India Ltd, Mumbai, India) beginning in October 2020. Intravitreal brolucizumab is currently approved for the treatment of two primary retinal disorders: neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). While it is formally approved for these two conditions, it is occasionally used off-label by retina specialists to treat other vascular chorioretinal diseases, such as macular edema secondary to retinal vein occlusion (RVO) or recalcitrant central serous chorioretinopathy (CSCR). With the smallest molecular weight of 26 kDa among the approved anti-VEGF agents, this drug is regarded as potentially more efficacious in penetrating retinal and choroidal vasculature.[13] Hence, the rationale for the therapeutic application of this molecule in patients with chronic CSC complicated by neovascularization is based on the fact that the underlying pathology resides deeper within the choroid. In this retrospective real-world study, we have analyzed the long-term safety and efficacy of brolucizumab, an off-label drug, given as a pro-nata regimen in recalcitrant cases of chronic CSC complicated by neovascularization. Methods This was a single-center retrospective case series analyzing patient records from January 2021 to July 2025. It included individuals diagnosed with chronic CSC complicated by neovascularization (pachychoroid neovasculopathy) who received off-label treatment with one or more doses of intravitreal Brolucizumab (Pagenax®). Invariably, all these patients of pachychoroid neovasculopathy had received at least three doses of intravitreal anti-VEGF injections other than brolucizumab, which included ranibizumab, aflibercept, and ranibizumab biosimilars, yet exhibited a poor response to the therapy. In addition to intravitreal anti-VEGF treatment, all patients had a history of previous interventions, including photodynamic therapy, oral mineralocorticoid antagonists, or focal laser photocoagulation. An inadequate response was characterized by persistent intraretinal or subretinal fluid and less than a 10% reduction in fluid volume from baseline. The study adhered to the Declaration of Helsinki, and ethical approval was waived due to its retrospective nature. Data collection was limited to clinical information, with confidentiality maintained. Common features of the spectrum included reduced fundal tessellation, RPE pigmentary anomalies, presence of pachydrusen, which are typically larger drusen present at posterior pole,[13] attenuation of the choriocapillaris with increased choroidal thickness and pachyvessels on enhanced-depth imaging optical coherence tomography (EDI-OCT), and choroidal hyperpermeability with dilated vessels on Indocyanine green angiography (ICGA). Chronic CSC was defined by persistent subretinal fluid of at least 4 months unresponsive to conservative treatment, with recurrent leaks on FFA (fundus fluorescein angiography). PNV was identified in patients with features of chronic CSC complicated via neovasculopathy evidenced by imaging signs such as type 1 macular neovascularization, shallow RPE elevation and persistent PEDs, sub-RPE branching neovascular networks on OCT-Angiography (OCT-A), and/or stippled hyperfluorescence with late leakage on FFA, along with other clinical features like the presence of pachydrusen.[14] We excluded patients who received PDT within 6 months, intravitreal injection of other anti-VEGF agents within 2 months, or any intraocular surgery within 3 months of the first brolucizumab injection. We also excluded patients with chronic CSC who did not demonstrate neovasculopathy as they are beyond the scope of our study. The diagnosis was made based on the patient’s previous records from the treating physician and the results of the multimodal imaging examinations to which the patient was subjected. Imaging procedures were consistently conducted on the same equipment, that is, EDI-OCT, FFA, and ICGA utilizing the SPECTRALIS HRA + OCT, Heidelberg Engineering, Heidelberg, Germany, as well as OCT-Angiography performed on the SD‐OCT RTVue® by Optovue, Inc., Fremont, CA. CST was defined as the distance between the internal limiting membrane and the outer border of the RPE under the foveal center. All these parameters were manually measured (in µm) by a single vitreo-retina specialist (SS) to reduce interpersonal bias. The primary aim was to measure functional improvement, exemplified by changes in BCVA from baseline to the final follow-up, with BCVA expressed in logMAR units derived from Snellen’s chart for statistical purposes. A secondary aim involved assessing the quantitative changes observed on EDI-OCT, specifically the variation in CST and PED height from baseline to final follow-up. Additionally, any ocular or systemic adverse events observed at each postoperative visit were documented, including intraocular pressure (IOP) elevations exceeding 22 mm Hg, signs of intraocular inflammation such as vitritis, retinitis, occlusive vasculitis, endophthalmitis, and retinal detachment. Statistical analysis Statistical analysis was performed on the Statistical Package for Social Sciences (SPSS) version 29.0 for Windows. The normality of data was tested by the Kolmogorov–Smirnov test. Descriptive statistics were employed to summarize the information. Statistical analysis was done using the Wilcoxon signed-rank test for assessing changes in BCVA and CST at 6 months, 1 year, and 2 years. Spearman’s correlation coefficient was used for correlation analysis. A P value less than 0.05 is considered significant at a 95% confidence level. Results A total of 30 eyes from 25 patients with recalcitrant chronic CSC complicated by neovascularization were included in the analysis. Of these, 19 were males and 6 females. All had received at least one intravitreal injection besides brolucizumab, with 26 eyes receiving two or more anti-VEGF injections, 18 eyes had been treated with oral eplerenone, and 4 eyes had a prior history of PDT. The mean age was 60.36 ± 14.51 years (range 35–88). All patients had at least 6 months of follow-up and were treated with intravitreal brolucizumab (Pagenax®) on a pro re nata (PRN) basis, with injections timed according to recurrence of fluid on EDI-OCT. Outcomes measured included changes in BCVA, CST, and PED from baseline to final follow-up, as well as the total injections administered. Nine eyes from eight patients had follow-up exceeding 2 years; we evaluated changes in BCVA and CST from baseline to 1 and 2 years and examined associations between injection count and changes in BCVA and CST. Outcomes at 6 months (n = 30): The mean BCVA changed from 0.38 ± 0.21 logMAR at baseline to 0.33 ± 0.22 logMAR, and the median BCVA changed from 0.44 at baseline to 0.30; however, this change was not statistically significant with a small effect size (P = 0.314, r = 0.312). Twelve eyes out of 30 eyes exhibited improvement in visual acuity by a minimum of 1 Snellen line, 15 eyes showed no change, and 3 eyes experienced deterioration by at least 1 Snellen line. Additionally, the mean CST changed from 328.03 ± 222.06 µm at baseline to 172.43 ± 78.76 µm, representing a highly significant anatomical improvement, with a large effect size (P < 0.001, r = 0.827). Seven out of 30 eyes showed a reduction in CST by more than 50%, demonstrating remarkable drying effect. Seventeen out of 30 eyes demonstrated PED at baseline; the mean changed from 262.35 ± 192.00 µm to 155.41 ± 123.00 µm, which was significant reduction in PED height with a large effect size (P = 0.027, r = 0.612). The average number of injections administered during this period was 1.97 ± 0.92, with a range of 1 to 4. To summarize, at the 6-month follow-up, the BCVA either remained stable or demonstrated a trend toward improvement. A significant reduction in CST and PED height indicates a pronounced drying effect of the medication [Fig. 1 and Table 1]. Imaging of an eye with chronic CSC complicated with neovasculopathy (PNV); (a) OCT scan at baseline showing flat irregular pigment epithelial detachment (FIPED) and subretinal fluid (SRF); (b) Reduction in SRF and flattening of PEDs post-treatment with yellow arrow heads pointing towards pachyvessels. (c) Further improvement in foveal anatomy; (d) OCT at last visit following five intravitreal injections of brolucizumab (Pagenax®) and 1 year of follow-up; (e) Clinical photograph of the right eye of the patient showing a pachydrusen marked as green arrow head; (f) OCT angiography at baseline showing a choroidal neovascular (CNV) complex; (g) Regressing CNV complex. (h) Fellow eye of the same patient showing pachydrusen pointed as yellow arrow. (i) Infrared image depicting the section of OCT taken through the pachydrusen. (j) OCT showing pachydrusen with underlying pachyvessels pointed as yellow triangle and choroidal thickness noted in pink as 313 microns Table 1Clinical outcomes after pro-re-nata Brolucizumab after 6 monthsCharacteristics (n=30)Baseline6-months P Wilcoxon rMean logMAR BCVA0.38±0.210.33±0.220.3140.312Median logMAR BCVA0.440.300.3140.312CST in μm328.03±222.06172.43±78.76<0.0010.827PED height in μm (in n=17)262.35±192.00155.41±123.000.0270.612 Clinical outcomes after pro-re-nata Brolucizumab after 6 months Extended Outcomes at Follow-up (n = 9): The mean BCVA shifted from 0.43 ± 0.22 logMAR at baseline to 0.45 ± 0.22 logMAR at 1 year (P = 0.853, r = 0.065), and subsequently to 0.44 ± 0.27 logMAR at 2 years (P = 0.685, r = 0.135), indicating a slight deterioration, however not significant. At the 1 and 2-year mark, the median change is near 0.0 logMAR, maintaining a constant value of 0.48. These fluctuations in BCVA were not statistically significant and exhibited a small effect size. Six out of nine eyes demonstrated either improvement or stability in visual acuity, while three out of nine eyes experienced a deterioration of at least one Snellen line. The difference in BCVA between 1 and 2 years was also not statistically significant (P = 0.854). The mean CST changed from 412.33 ± 240.82 µm at baseline to 271.11 ± 238.93 µm at 1 year (P = 0.009, r = 0.940) and further decreased to 164.44 ± 42.41 µm at 2 years (P = 0.004, r = 0.962). This represents a highly significant anatomical improvement with a large effect size. The mean additional reduction from the first to the second year was 106.67 ± 211.23 µm (P = 0.382, r = 0.357), which was not statistically significant and exhibited a small to medium effect size. The average number of injections administered was 4.11 ± 1.05 (range 3–6) during the first year and 7.11 ± 1.54 (range 5–10) during the second year. Out of nine eyes of eight patients, improvement in BCVA was noted in two eyes, four eyes exhibited no change, and three eyes showed worsened BCVA at the end of the first and second years. None of the eyes subjected to treatment exhibited any signs of intraocular inflammation, increased IOP, or retinal detachment. Additionally, no systemic adverse events were observed or reported throughout the duration of the treatment [Fig. 2 and Table 2]. The figure comprises three panels comparing visual and anatomical outcomes over three follow-up periods (6 months, 1 year, and 2 years): (a) Effect Sizes by Follow-up Period: Blue bars (BCVA effect size) depict small effect size. Red bars (CST effect size) are large and consistent. Dashed horizontal lines mark effect-size benchmarks (e.g. 0.2 small, 0.5 medium). (b) BCVA Changes by Follow-up Period (logMAR): At 6 months (blue), the median BCVA change is about –0.14 logMAR (improvement), with the interquartile range from –0.25 to 0.0 and outliers to –0.55 and +0.3. At 1 year (red), the median change is near 0.0 logMAR, with a tighter distribution and mild outliers. At 2 years (gold), the median change is again near 0.0 logMAR (slight worsening), with wider variability and outliers down to –0.6 and up to +0.25. (c) CST Changes by Follow-up Period (µm). At 6 months, the median CST reduction is about –100 µm, IQR roughly –150 to –50, with outliers down to –800 and up to –50. At 1 year, the median reduction is about –160 µm, IQR –240 to –120, with similar outliers. At 2 years, the median reduction is about –200 µm, IQR –260 to –150, with outliers to –750 Table 2Extended outcomes after 1 year and 2 yearslogMAR BCVABaseline Mean0.43±0.22 P Wilcoxon r1-year Mean0.45±0.220.8530.0652-year Mean0.44±0.270.6850.135 Baseline Median 0.48 P Wilcoxon r 1-year Median0.480.9670.0422-year Median0.480.6190.091 Central Subfield Thickness in μm Baseline Mean 412.33±240.82 P Wilcoxon r 1-year Mean271.11±238.930.0090.9402-year Mean164.44±42.410.0040.962logMAR BCVA: Logarithm of the Minimum Angle of Resolution Best Corrected Visual Acuity. CST: Central Subfield Thickness. PED: Pigment Epithelium Detachment. PDT: Photodynamic therapy. Anti-VEGF: Anti-Vascular Endothelial Growth Factor Extended outcomes after 1 year and 2 years logMAR BCVA: Logarithm of the Minimum Angle of Resolution Best Corrected Visual Acuity. CST: Central Subfield Thickness. PED: Pigment Epithelium Detachment. PDT: Photodynamic therapy. Anti-VEGF: Anti-Vascular Endothelial Growth Factor Correlation analysis (n = 9): The number of injections did not demonstrate a correlation with the improvement in BCVA at the end of the first year (ρ = 0.009, P = 0.982) or at the end of the second year (ρ = -0.294, P = 0.443). Nonetheless, pooled data indicated a weak negative correlation between the change in BCVA and the number of injections (ρ = -0.25, P = 0.144), which was not statistically significant. A weak positive correlation was observed between the change in CST and the number of injections (ρ = 0.35, P = 0.008) [Fig. 3]. The figure shows two scatterplots correlating the number of brolucizumab injections with visual and anatomical changes: (a) Injections versus BCVA Change: Each point represents one eye’s logMAR BCVA change plotted against its total number of injections. The red trend line slopes slightly downward, indicating a negative correlation (ρ = -0.25), but this is not statistically significant (P = 0.144). This suggests that eyes requiring more injections tended to have slightly less BCVA improvement, though the association is weak and could occur by chance. (b) Injections versus CST Change: Each point represents one eye’s reduction in central subfield thickness (CST in µm) plotted against its total injections. The red trend line slopes upward, indicating a positive correlation (ρ =0.352) that is statistically significant (P = 0.008). This means eyes receiving more injections showed greater anatomical improvement (larger CST reduction), demonstrating a moderate, significant association between injection number and macular drying Discussion The pachychoroid spectrum has become a significant focus in retinal research and clinical practice due to advances in imaging technology, evolving disease definitions, and clear therapeutic implications.[15] Since its introduction around 2013, the concept has expanded from central serous chorioretinopathy (CSCR) and pachychoroid pigment epitheliopathy (PPE) to include pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy (PCV), peripapillary pachychoroid syndrome (PPS), focal choroidal excavation (FCE), peripapillary pachychoroid neovasculopathy, and peripheral exudative hemorrhagic chorioretinopathy.[16] Pachychoroid-driven neovascularization often responds differently to anti-VEGF agents and photodynamic therapy compared to age-related macular degeneration, requiring tailored treatment protocols. Patients with chronic CSCR who develop PNV tend to experience higher recurrence rates of subretinal fluid and worse visual outcomes and may need more intensive intervention than those with uncomplicated CSCR or initial PNV presentation.[17181920] It was the work of Chhablani et al. in 2015,[20] where the role of anti-VEGFs was discussed for managing CNV secondary to CSCR. This cohort received intravitreal injections of bevacizumab, ranibizumab, or aflibercept and demonstrated visual acuity improvement in 26% and stabilization in 41.3% of patients post anti-VEGF treatment. Ranibizumab has been used on-label for PNV associated with CSCR ever since the MINERVA study proved its safety and efficacy in choroidal neovascularization because of uncommon causes.[21] A 2019 retrospective study by Jung et al.[10] analyzed that in eyes with PVN, Aflibercept showed superior efficacy and greater reduction in subfoveal choroidal thickness than ranibizumab. Additionally, patients unresponsive to ranibizumab responded well to aflibercept. In 2021, Schworm et al.[22] undertook a retrospective study to evaluate the effect of ranibizumab on choroidal thickness within the pachychoroid spectrum. The study identified a significant decrease in choroidal thickness, a phenomenon termed “vanishing pachychoroid” phenomenon. Although anti-VEGFs are being utilized off-label for managing Chronic CSR complicated by CNV and PNV related to the pachychoroid spectrum, the question remains which anti-VEGF agent to employ from the numerous options available in the therapeutic arsenal. When addressing diseases within the pachychoroid spectrum, where the pathology primarily resides in the choroidal vasculature, the focus is on targeting the choroid using current treatment modalities. This approach provides the rationale for selecting an anti-VEGF agent with the inherent capacity to penetrate deeply into the choroid, thereby facilitating the reduction of exudation and concurrently enhancing treatment cost-effectiveness through increased durability. The BROCS study was the first to examine the use of brolucizumab for PNV in patients with chronic CSC. It evaluated eyes treated with intravitreal brolucizumab, assessing outcomes at baseline, 1 month, and final follow-up. Most eyes experienced complete fluid reabsorption, and the majority showed either improved or stable vision. No serious ocular or systemic adverse events were reported with an IOI rate of zero. This contrasts with previous studies on AMD, likely due to differences in sample size, patient characteristics, and pathology. The study confirmed the efficacy of brolucizumab in both naïve and non-naïve PNV cases.[11] Subsequently, the efficacy of brolucizumab was assessed through additional cohorts and case series, demonstrating favorable outcomes—particularly anatomical—in patients with chronic CSC with or without PNV over follow-up periods ranging from 1 month to 1 year. Ribarich et al.[23] showed that switching to brolucizumab in PNV eyes resulted in significant anatomical improvements, including reduction of subretinal fluid, resolution of subretinal hyper-reflective material, and decreased choroidal thickness. Huang et al.[24] conducted a short-term retrospective cohort study and found that a single brolucizumab shot led to superior fluid resolution, greater reduction in central choroidal thickness, and BCVA outcomes comparable to half-dose PDT and aflibercept, with only one case of mild vitritis observed. Jeong et al.[25] studied treatment-naïve PNV eyes over a year, finding that both aflibercept and brolucizumab improved BCVA, CMT, and subfoveal choroidal thickness; however, brolucizumab caused greater early reductions and increased Choroidal Vascularity Index, with no major adverse events. Ramamurthy et al.[26] conducted a pilot study with five chronic CSCR eyes without CNVM, showing significant functional and anatomical improvements after 1 month, with no adverse events. In our retrospective case series, we analyzed the records of patients with recalcitrant chronic CSC who developed neovasculopathy with confirmed pachychoroid disease, evidenced by multimodal imaging [Figs. 4 and 5]. These patients were treated with brolucizumab (Pagenax®) under a PRN regimen. We evaluated anatomical and visual outcomes in 30 eyes of 25 patients from baseline to 6 months. At 6 months, 90% of eyes showed stable or improved visual acuity. A significant reduction in CST was observed, indicating effective drying that helped maintain visual acuity. Additionally, nine eyes of eight patients were reevaluated for changes in BCVA and CST at 1 and 2 years, showing that 66.7% (6/9) and 55.6% (5/9) of eyes, respectively, had stable or improved BCVA. OCT-A image of a chronic CSC complicated by neovascularization (pachychoroid neovasculopathy). (a) Angiogram at the level of the choriocapillaris slab; red arrow pointing at gridlines intersecting at a neovascular complex. (b) En-Face image of the same. (c) Corresponding B-Scan image with flow Doppler; red arrowhead pointing toward the increased flow in the neovascular complex. (d) Corresponding B-Scan image showing subretinal fluid with adjacent undulating RPE, suggesting a Type-1 neovascular complex. (e) Red box showing the corresponding en face slab setting at choriocapillaris Combined FFA (Left side) and ICGA (Right side) of a patient with chronic CSC complicated by neovascularization (pachychoroid neovasculopathy). (a) Arteriolar phase of FFA with the corresponding early phase of ICGA. Red arrows in ICGA pointing toward hypocyanescent areas of choriocapillary filling delay, suggesting potential ischemia. (b) Arteriovenous phase of FFA with corresponding early phase of ICGA. Red arrows in ICGA pointing towards the dilated vessels of Haller’s layer. (c) Late venous phase of FFA with corresponding Early phase of ICGA. Red arrow head in FFA pointing toward stippled hyperfluorescence. Red arrows in ICGA pointing at patchy areas of hypercyanescence corresponding to prominence of Haller’s vessels and choroidal watershed zone. (d) Recirculation phase of FFA with corresponding mid-phase of ICGA. FFA showing same persisting stippled hyperfluorescence. Red arrows in ICGA pointing at patchy areas of hypercyanescence suggesting both choroidal hyperpermeability and neovascular leakage. (e) Recirculation phase of FFA with corresponding Late phase of ICGA. Red arrow head FFA pointing at increasing stippled hyperfluorescence. Red arrows in ICGA pointing at increasing late-staining hypercyanescence, hallmark of active CNVM. (f) Recirculation phase of FFA with the corresponding Late phase of ICGA. FFA showing late disc staining. Red arrows in ICGA pointing at persistent hyperfluorescence with centrifugal displacement, suggesting late surrounding staining of the CNVM plaque The visual enhancement is most effectively demonstrated within 6 months of initiating the PRN regimen. The treatment exhibited significant drying of the macula, which persisted throughout prolonged follow-up periods. This anatomical improvement subsequently facilitates the restoration of vision. It is also observed in the extended outcomes that the mean BCVA either remains stable or diminishes in some cases despite ongoing treatment. This phenomenon can be ascribed to the chronic nature of the disease and the permanent alterations to the RPE-photoreceptor complex. The correlative analysis demonstrated a statistically significant positive correlation between the reduction of CST and the number of intravitreal injections administered. Conversely, a statistically nonsignificant negative correlation was observed between improvements in BCVA and the number of injections. The observed trend suggests that an increased number of injections may be weakly associated with less favorable BCVA outcomes. This phenomenon may be attributable to treatment-resistant cases requiring a higher frequency of injections, and a greater number of injections could correspond with more substantial CST reduction. Published case series and cohort studies involving intravitreal brolucizumab in the pachychoroid spectrum indicate that the most common regimen is an initial “loading” phase of three monthly injections, followed by an OCT-guided PRN schedule. We included only patients treated with a PRN dose, concluding that this regimen stabilizes vision and achieves anatomical improvements, such as CST reduction and PEDs resolution, in previously treated and recalcitrant chronic CSC cases complicated by neovascularization (PNV). With a molecular weight of 26 kDa, brolucizumab 6 mg in 0.05 mL offers a high molar concentration that positively impacts its durability as well as accounts for its effective penetration into the retina and choroid. Hence, the rationale of using intravitreal Pagenax® in pachychoroid disease with its potential to target the site of pathology, that is, choroidal vasculature, is promising.[27] The post-hoc analysis of Phase III HAWK and HARRIER studies reported an overall intraocular inflammation (IOI) incidence of 4.6% associated with intravitreal brolucizumab injections.[28] In contrast, the VRSI study group assessing brolucizumab (Pagenax®) found a lower incidence of 0.79%.[29] Adverse events in brolucizumab use for pachychoroid spectrum disorders are generally rare.[1123242526] Our analysis of 30 eyes receiving 97 injections observed no immune, inflammatory, or other ocular and systemic adverse events, though the small sample size limits conclusions. The lower incidence of immune or inflammatory reactions in the Indian subcontinent may be due to genetic diversity affecting biological responses, which warrants further research. The retrospective design and relatively small sample size constitute significant limitations on the statistical power of our study. Within this retrospective cohort, injections were administered under a PRN regimen. Comparative analysis with treat-and-extend or monthly dosing protocols was not feasible due to the retrospective methodology and the absence of a comparative group. Consequently, the lack of a control group precludes definitive conclusions regarding the superiority of intravitreal brolucizumab (Pagenax®) over other available anti-VEGF therapies. Larger, prospective studies are requisite to substantiate these findings. It should be noted that the authors have not investigated the role of brolucizumab in uncomplicated CSCR, that is, when there is no evidence of neovascularization, as this was outside the scope of this study. Therefore, they do not advocate the off-label use of brolucizumab for the treatment of CSCR without neovascularization. Conclusion With this report, the authors aimed to demonstrate the long-term outcome of brolucizumab in PNV patients. However, without a comparative group, the superiority of brolucizumab over other intravitreal anti-VEGF agents cannot be confirmed. The authors attempted to leverage the better drying effect of the agent, as shown in the HAWK and HARRIER studies, in cases where the underlying pathology involves increased exudation. Hence, this provides the rationale. The pro re nata approach of intravitreal brolucizumab has demonstrated considerable efficacy in managing cases of Chronic CSC with CNV (PNV) that are refractory to conventional treatments. The anatomical improvements were notably significant, as evidenced by reductions in CST and the resolution of PED throughout the follow-up period. In light of the unavailability of the Verteporfin dye used for PDT, alternative effective strategies should be considered. Hence, off-label use of intravitreal brolucizumab may be regarded as one of the treatment options for recalcitrant cases of chronic CSC with CNV (PNV). Conflicts of interest There are no conflicts of interest.